Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. - Abstract - Europe PMC
JCM | Free Full-Text | Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study - Annals of Oncology
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
Verzenios, INN-abemaciclib
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
FDA Provides Insight Into Abemaciclib Approval for High-Risk Early Breast Cancer
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Kaplan–Meier curve for overall survival in the premenopausal population... | Download Scientific Diagram
Other tumors. A, abemaciclib prolongs overall survival in an... | Download Scientific Diagram
Update Shows Long-Term Survival Benefit with Abemaciclib Plus
Dana-Farber News on Twitter: "#BreastCancer results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast
K-M curve and parametric survival distributions for PFS. PFS,... | Download Scientific Diagram
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival | MDedge Hematology and Oncology
Combination of abemaciclib and adjuvant hormone therapy increases invasive disease-free survival in high-risk early breast cancer RH + HER2- Onco Americas
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
